S tent-assisted coiling (SAC) has been used with increasing frequency over the past few years, particularly for addressing endovascular treatment of wide-neck intracranial aneurysms. Chalouhi et al, 1 in the largest series published to our knowledge, reported a 3% combined permanent morbidity and mortality rate after SAC of 552 aneurysms. However, these results concerned the Neuroform stent (Stryker Neurovascular, Fremont, California) and Enterprise stent (Codman, Miami, Florida). Considering the Solitaire AB stent (Covidien, Irvine, California), we recently reported the immediate clinical and anatomic posttreatment results of a consecutive prospective registry conducted in 7 European centers. 2 However, the influence of the Solitaire AB stent on the angiographic outcome after endovascular treatment of intracranial aneurysms is unknown because of the lack of prospective data.
Our objective was to evaluate the mid-term anatomic results in 64 intracranial aneurysms treated with the Solitaire AB stent and included in a prospective multicenter European registry.
METHODS SOLARE (SOLitaire Aneurysm Remodeling) Protocol and Population
from a parent vessel with a diameter of 3.0 mm or greater and 6.0 mm or less with a wide-neck ($4 mm) or dome-to-neck ratio less than 2 were included. Fusiform and dissecting aneurysms, as well as aneurysms associated with an arteriovenous malformation, were excluded. The use of a stent other than the Solitaire AB device was considered as an exclusion criterion. Patients with contraindications to heparin, clopidogrel, or aspirin were also excluded. No antiplatelet medication protocol was specified in the SOLARE study, as antiplatelet drugs were administered at the discretion of each investigating site. The protocol was approved by the ethics committee of each center. Written informed consent was obtained from each patient/legally authorized representative before entry into the study.
A total of 64 patients (53 women and 11 men; age range, 26-84 years; mean age, 53.3 years) harboring 65 aneurysms were included. Clinical presentation was subarachnoid hemorrhage in 5 patients (7.9%). Hunt and Hess scale was grade I in 3 patients (4.7%) and grade II in 2 patients (3.2%). Unruptured aneurysms were present in 59 patients (93.7%). Most aneurysms (81.5%) were located in the anterior circulation, and the carotid-ophthalmic segment was the most frequent location (27.7%). The mean width of the aneurysm sac was 7.5 mm, and the mean diameter of aneurysm neck was 4.7 mm. The mean dome-to-neck ratio of the aneurysm was 1.6.
Follow-up Protocol
Anatomic results were evaluated on angiogram or magnetic resonance angiogram, including selective contrast injections and 4 projections. For each patient, the postembolization and mid-term (6 month 6 15 days) degree of aneurysmal occlusion was assessed by the core laboratory (Frederic Ricolfi, MD, Radiology Department, University Hospital, Dijon, France) for 63 patients having 64 aneurysms. It was defined by using the simplified 3-point Jean Raymond classification scale: complete occlusion, neck remnant, and aneurysm remnant. 3 Recanalization and progressive occlusion were defined as a change in the Raymond classification, comparing the rate of occlusion postembolization and on midterm follow-up. Recanalization was defined as a worsening of classification: complete occlusion to neck remnant, neck remnant to aneurysm remnant, or complete occlusion to aneurysm remnant. Progressive occlusion was defined as improvement of classification.
Clinical Follow-up
Bleeding or rebleeding occurrence during the period of follow-up was evaluated.
Data Analysis
Clinical and procedural data were collected and entered via an electronic Web site by the investigator. Quality of data, exhaustivity, and consecutiveness were checked by clinical research associates at each site. Statistical analysis was independently conducted.
All reported adverse events related to the treatment were analyzed blindly by a neuroradiologist (F.T.) and are described in this series. Permanent morbidity and mortality of endovascular treatment were evaluated before and after treatment, at hospital discharge, and at 1-and 6-month follow-up. Morbidity was defined as a modified Rankin Scale (mRS) score of 2 to 5. When preoperative mRS score was greater than 1, morbidity was defined by any increase of mRS. Any modification within 30 days after endovascular treatment was designated as treatment related.
Any death within 30 days of endovascular treatment was designated a treatment-related death.
RESULTS

Clinical Results
Of the 64 patients (65 aneurysms) who were initially included in the registry, 1 was excluded (neck length ,4 mm), and 1 missed the 6-month follow-up. Finally, 62 patients had a clinical followup. The 6-month clinical results are reported in Table 1 . No deaths were reported during the follow-up period. Only 1 patient experienced slight worsening at 6 months, from an mRS score of 0 at baseline to a score of 1 at 6-month follow-up. The permanent 6-month morbidity rate was 0%, and the mortality rate was 0%.
Anatomic Results
According to the core laboratory evaluation, at 6 months, 4 aneurysms were not assessed (1 with no stent placed, 1 with no coils placed, 1 missed visit, 1 visit by phone only), and 6 were not successfully evaluated due to stent artifacts (magnetic resonance imaging [MRI] ). Of the 65 aneurysms that were initially included in the registry, 55 had mid-term anatomic follow-up by angiography after treatment. Progressive occlusion occurred in 17 aneurysms (30.9%), and recurrence in 8 aneurysms (14.5%) ( Table 2) . Complete occlusion was obtained in 33 (60%) of 55 aneurysms at 6 months compared with 27 (42.1%) of 63 aneurysms in the postprocedure evaluation (Figures 1 and 2 ). The number of aneurysms with a residual neck remnant decreased from 25 of 64 aneurysms (39.1%) to 16 aneurysms (29.1%). Parent artery patency was seen in all aneurysms.
At 6 months, all of the assessable aneurysms had stable stent placement with complete aneurysm neck coverage.
DISCUSSION
The immediate safety and efficacy of the Solitaire AB stent in the treatment of wide necked intracranial aneurysms were demonstrated and reported previously. 2 In this study, we assessed 
the mid-term clinical and anatomic results of Solitaire AB SAC of wide-necked intracranial aneurysms. The SOLARE study is the first prospective, consecutive, multicenter study of the Solitaire AB stent.
Description of Solitaire AB Stent and Technical Aspects
The Solitaire AB stent is used to retain coils within the aneurysm, thus reducing the risk of embolic complications from coil herniation into the parent artery. Compared with Neuroform and Enterprise stents, the Solitaire AB stent is a self-expanding nitinol device that could be completely deployed and fully retrieved at the end of the procedure. Retrievability is a unique feature of the Solitaire AB stent that allows stent repositioning or removal if desired by the treating physician. 4 The goal of the study was to assess whether the characteristics of this device affected the benefits to the patient. Apart from retrievability, this set of characteristics cannot be individually evaluated, and their evaluation is reflected in the global results as safety and efficacy. In the SOLARE study, the stent was used but retrieved at the end of the coiling in 1 patient.
Safety of the Solitaire AB Stent
The results of SAC vary widely across different studies. In a French series of 216 aneurysms treated with stents, the rates of permanent morbidity and mortality were as high as 7.4% and 4.6%, respectively. 5 Elsewhere, morbidity and mortality rates with SAC were found to be lower. [6] [7] [8] [9] In this series, mortality was 0%, and permanent morbidity was 0%, which confirms the safety of the Solitaire SAC for wide-necked intracranial aneurysms. In the retrospective series of 104 intracranial aneurysms a At the postprocedure assessment, 1 aneurysm occlusion status was not assessed because no stent was placed. At 6 months, 10 aneurysms has no follow-up: 1 with no stent placed, 2 lost to follow-up, 1 visit by phone only, and 6 due to stent artifacts. treated with the Solitaire AB stent reported by Clajus et al, 9 the morbidity and mortality were evaluated at 3.9% and 2.9, respectively. These results are not different from those reported in the large series of 508 patients treated with Neuroform and Enterprise stents. In these series, the procedure-related morbidity and mortality rates were 3%. 1 
Mid-term Anatomic Results of Solitaire AB Stent
Despite the fact that this series includes wide-necked aneurysms, the mid-term rates of recanalization were low (14.5%). The recurrence rate in our series is largely in line with previously reported SAC series. Using Neuroform stents, Gentric et al 10 reported a 9.7% rate of recurrence, whereas Maldonado et al 8 reported a 14.5% rate of recurrence rates after Neuroform SAC of 76 aneurysms. A limitation in our series is the fact that at 6 months, 10 aneurysms were not adequately assessed by imaging according to the core laboratory, including 6 due to stent artifacts on MRI. To date, artifacts introduced by stents limit the value of MRI as a follow-up modality after SAC. 12 Contrast administration also improved vessel lumen visualization. 13 Conventional catheter angiography remains the gold standard. There is a need for even later follow-up to assess the rate of long-term recurrence.
Intracranial stents offer scaffolding for reconstruction of the intimal layer of the parent artery at the aneurysm neck and may also promote progressive thrombosis. 5, 9, 10, [14] [15] [16] In the retrospective series of Clajus et al, 9 dealing with 104 aneurysms treated with the Solitaire AB stent, 39.2% of the aneurysms revealed further occlusion. In the literature survey of Shapiro et al, 13 approximately 45% of 1510 aneurysms were completely occluded at first treatment session, increasing to 61% on the median 6-month follow-up (695 patients provided imaging). Fiorella et al 14 reported, in patients treated with Neuroform stent-assisted coiling, a progressive thrombosis in 52% of the cases. Piotin et al 4 reported, by using Neuroform and Enterprise stents, further thrombosis in 72.6% of aneurysms with significantly fewer recurrences in the stented aneurysm group despite inclusion of larger aneurysms with lower packing densities. The final results of this series are lower than those previously reported, with progressive thrombosis of the aneurysm documented in 30.9% of cases.
Although SAC has a lower recurrence rate than conventional coiling, 40% of aneurysms were not completely occluded at 6 months in our series. 17 This rate compares well with the recent review of Shapiro et al. 13 To date, the predictive factors of progressive thrombosis failure are not well known. This could be related to different designs of available intracranial stents: the open-cell design of the Neuroform stent and the closed-cell design of the Enterprise and Solitaire AB stent. Open-cell design stents could, in principle, adjust better to curved and tortuous vasculature, but they may be associated with some adverse mechanistic effects, such as increased cell opening or strut prolapse. 18 However, in the series of Chalouhi et al 1 dealing with 508 patients treated with Neuroform and Enterprise stents, closed-cell stents were associated with significantly lower aneurysm recanalization rates. Thus, the closed-cell design of the Enterprise stent may more efficiently alter intra-aneurysmal hemodynamic parameters and promote saccular thrombosis.
We observed no case of in-stent stenosis during the angiographic follow-up period, comparing well with the series of Clajus et al. 9 Forty-nine patients were followed for 13.6 months, and no clinically relevant in-stent stenosis was observed. Neuroform use has been associated with a 5.8% occurrence of delayed moderate or severe in-stent stenosis, 22% of which were symptomatic. 16 To date, the rate of Enterprise in-stent stenosis is not well known because only initial results of Enterprise stent use in SAC was reported. and no follow-up data outside the immediate perioperative were available. 7 
CONCLUSION
SAC of wide-necked intracranial aneurysms was found to be safe and effective with the Solitaire AB stent at 6-month follow-up. Angiographic results improve with time due to progressive thrombosis of the aneurysm.
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